vs
Datavault AI Inc.（DVLT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Datavault AI Inc.的季度营收约是REGENXBIO Inc.的1.1倍（$33.8M vs $30.3M），Datavault AI Inc.净利率更高（2.0% vs -221.3%，领先223.3%），Datavault AI Inc.同比增速更快（3649.6% vs 43.0%），Datavault AI Inc.自由现金流更多（$-734.0K vs $-52.8M），过去两年Datavault AI Inc.的营收复合增速更高（1051.7% vs 39.4%）
Datavault AI Inc是一家人工智能科技企业，主打AI驱动的数据管理与集成解决方案，主要服务北美地区的企业客户，帮助客户整合分散数据资产，优化分析流程，加速机器学习模型的开发与落地。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DVLT vs RGNX — 直观对比
营收规模更大
DVLT
是对方的1.1倍
$30.3M
营收增速更快
DVLT
高出3606.6%
43.0%
净利率更高
DVLT
高出223.3%
-221.3%
自由现金流更多
DVLT
多$52.1M
$-52.8M
两年增速更快
DVLT
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.8M | $30.3M |
| 净利润 | $661.0K | $-67.1M |
| 毛利率 | 89.3% | — |
| 营业利润率 | 12.3% | -190.0% |
| 净利率 | 2.0% | -221.3% |
| 营收同比 | 3649.6% | 43.0% |
| 净利润同比 | 110.4% | -31.2% |
| 每股收益（稀释后） | $0.53 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVLTRGNX
| Q4 25 | $33.8M | $30.3M | ||
| Q3 25 | $2.9M | $29.7M | ||
| Q2 25 | $1.7M | $21.4M | ||
| Q1 25 | $629.0K | $89.0M | ||
| Q4 24 | $902.0K | $21.2M | ||
| Q3 24 | $1.2M | $24.2M | ||
| Q2 24 | $345.0K | $22.3M | ||
| Q1 24 | $255.0K | $15.6M |
净利润DVLTRGNX
| Q4 25 | $661.0K | $-67.1M | ||
| Q3 25 | $-33.0M | $-61.9M | ||
| Q2 25 | $-37.1M | $-70.9M | ||
| Q1 25 | $-9.6M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-5.1M | $-59.6M | ||
| Q2 24 | $-42.7M | $-53.0M | ||
| Q1 24 | $2.7M | $-63.3M |
毛利率DVLTRGNX
| Q4 25 | 89.3% | — | ||
| Q3 25 | 3.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 11.0% | — | ||
| Q4 24 | 24.6% | 70.2% | ||
| Q3 24 | 19.3% | 48.8% | ||
| Q2 24 | 3.2% | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DVLTRGNX
| Q4 25 | 12.3% | -190.0% | ||
| Q3 25 | -508.1% | -176.3% | ||
| Q2 25 | -718.1% | -296.3% | ||
| Q1 25 | -1499.4% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | -447.4% | -256.6% | ||
| Q2 24 | -1566.7% | -251.3% | ||
| Q1 24 | -1630.6% | -408.8% |
净利率DVLTRGNX
| Q4 25 | 2.0% | -221.3% | ||
| Q3 25 | -1135.5% | -208.3% | ||
| Q2 25 | -2139.3% | -331.8% | ||
| Q1 25 | -1520.3% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | -434.5% | -246.3% | ||
| Q2 24 | -12366.7% | -237.7% | ||
| Q1 24 | 1061.6% | -405.4% |
每股收益（稀释后）DVLTRGNX
| Q4 25 | $0.53 | $-1.30 | ||
| Q3 25 | $-0.33 | $-1.20 | ||
| Q2 25 | $-0.54 | $-1.38 | ||
| Q1 25 | $-0.18 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-1.39 | $-1.17 | ||
| Q2 24 | $-11.89 | $-1.05 | ||
| Q1 24 | $-5.35 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $238.0M | $102.7M |
| 总资产 | $274.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DVLTRGNX
| Q4 25 | $2.0M | $230.1M | ||
| Q3 25 | $1.7M | $274.2M | ||
| Q2 25 | $662.0K | $323.3M | ||
| Q1 25 | $171.0K | $267.9M | ||
| Q4 24 | $3.3M | $234.7M | ||
| Q3 24 | $3.9M | $255.5M | ||
| Q2 24 | $6.1M | $290.4M | ||
| Q1 24 | $2.8M | $338.7M |
股东权益DVLTRGNX
| Q4 25 | $238.0M | $102.7M | ||
| Q3 25 | $99.5M | $161.5M | ||
| Q2 25 | $74.1M | $213.7M | ||
| Q1 25 | $81.7M | $274.2M | ||
| Q4 24 | $85.7M | $259.7M | ||
| Q3 24 | $4.3M | $301.4M | ||
| Q2 24 | $6.4M | $348.3M | ||
| Q1 24 | $-2.7M | $390.7M |
总资产DVLTRGNX
| Q4 25 | $274.7M | $453.0M | ||
| Q3 25 | $138.7M | $525.2M | ||
| Q2 25 | $120.7M | $581.0M | ||
| Q1 25 | $95.7M | $490.9M | ||
| Q4 24 | $100.6M | $466.0M | ||
| Q3 24 | $8.0M | $519.1M | ||
| Q2 24 | $10.6M | $569.4M | ||
| Q1 24 | $6.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-406.0K | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-734.0K | $-52.8M |
| 自由现金流率自由现金流/营收 | -2.2% | -174.0% |
| 资本支出强度资本支出/营收 | 1.0% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.61× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DVLTRGNX
| Q4 25 | $-406.0K | $-52.3M | ||
| Q3 25 | $-10.4M | $-56.0M | ||
| Q2 25 | $-6.8M | $-49.3M | ||
| Q1 25 | $-6.0M | $33.6M | ||
| Q4 24 | $-17.5M | $-31.6M | ||
| Q3 24 | $-4.2M | $-40.5M | ||
| Q2 24 | $-5.5M | $-45.5M | ||
| Q1 24 | $-3.5M | $-55.5M |
自由现金流DVLTRGNX
| Q4 25 | $-734.0K | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-6.1M | $32.6M | ||
| Q4 24 | $-17.6M | $-32.7M | ||
| Q3 24 | $-4.2M | $-40.9M | ||
| Q2 24 | $-5.5M | $-46.0M | ||
| Q1 24 | $-3.5M | $-56.0M |
自由现金流率DVLTRGNX
| Q4 25 | -2.2% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -966.0% | 36.6% | ||
| Q4 24 | -1946.9% | -154.2% | ||
| Q3 24 | -361.7% | -168.9% | ||
| Q2 24 | -1599.7% | -206.2% | ||
| Q1 24 | -1390.6% | -358.5% |
资本支出强度DVLTRGNX
| Q4 25 | 1.0% | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 8.3% | 1.2% | ||
| Q4 24 | 3.9% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 4.1% | 2.1% | ||
| Q1 24 | 2.4% | 3.6% |
现金转化率DVLTRGNX
| Q4 25 | -0.61× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.31× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVLT
| Eos Technology Holdings Inc. | $30.0M | 89% |
| Consumer Audio Products Components And Other Revenue Net | $3.2M | 9% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
